ADLM Annual Scientific Meeting & Clinical Lab Expo 2026

David M. Nathan, MD, is a Professor of Medicine at Harvard Medical School. He founded the Diabetes Center and directs the Clinical Research Center at Massachusetts General Hospital in Boston. An internationally acclaimed diabetes expert, he performed early, seminal studies to establish the HbA1c assay and conducted the first clinical studies with GLP-1 therapy in diabetes. Dr. Nathan is best known for his leadership of some of the most important studies in the treatment and prevention of diabetes including the Diabetes Control and Complications Trial and the Epidemiology of Diabetes Interventions and Complications Study in type 1 diabetes, and the Diabetes Prevention Program and the GRADE study in type 2 diabetes. David was awarded the Outstanding Clinician Award in 2002 and the inaugural Outstanding Achievement in Clinical Diabetes Research Award in 2015, both from the American Diabetes Association, and the 2010 Distinguished Scientist Award from the National Institute of Diabetes and Digestive and Kidney Diseases.

Kathleen A. McMonigal, MD, FCAP, is the Director of Clinical Laboratories for the National Aeronautics and Space Administration at the Lyndon B. Johnson Space Center in Houston, Texas. Dr. McMonigal oversees astronaut and occupational medicine laboratory testing at NASA.

Dr. Leeya F. Pinder is a distinguished gynecologic oncologist and Associate Professor at the University of Cincinnati. She also serves as the Associate Director for Cancer Control and Population Sciences at the University of Cincinnati Cancer Center. Dr. Pinder is deeply committed to improving women's health worldwide.

Dr. Arun Wiita is a physician-scientist and Professor in the Dept. of Laboratory Medicine and Dept. of Bioengineering & Therapeutic Sciences at the University of California, San Francisco. Dr. Wiita’s research laboratory focuses on mass spectrometry-based proteomics, target discovery, protein engineering, and cellular engineering toward the development of novel immunotherapies for hematologic malignancies, while his clinical duties center on molecular genomic pathology. Dr. Wiita also directs the UCSF Stephen and Nancy Grand Multiple Myeloma Translational Initiative (MMTI) Laboratory. Dr. Wiita is a prior recipient of the NIH Director’s New Innovator Award, a Clinical Scientist Development Award from the Doris Duke Charitable Foundation, and a Chan Zuckerberg Biohub Investigator Award, among others. He is also an elected member of the American Society for Clinical Investigation. He completed his residency in Clinical Pathology at UCSF, his MD and PhD at Columbia, with graduate training in single molecule biophysics, and undergraduate studies in Chemistry at Princeton.